EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
Geert R. D'Haens 1
Marla C. Dubinsky 2
Peter Irving 3
Xingyuan Li 4
Stefanie Howaldt 5
Juris Pokrotnieks 6
Kathryn Krueger 6
Janelle Laskowski 6
Trevor Lissoos 6
Joe Milata 6
1 Amsterdam University Medical Centers, Amsterdam, Netherlands
2 Icahn School of Medicine at Mount Sinai, New York City, United States
3 Guy´s and St Thomas´ Hospital, London, United Kingdom
4 Eli Lilly and Company, Indianapolis, United States
5 Research Institute for IBD-HaFCED e.K., Hamburg, Germany
6 Riga Stradins University, Riga, Latvia
Topic
IBD, Nurses, Primary Care
Conference
UEG Week Vienna 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]